Atossa Genetics (ATOS) Posts Narrower Q2 Loss
Get Alerts ATOS Hot Sheet
Join SI Premium – FREE
Atossa Genetics (NASDAQ: ATOS) reported Q2 EPS of ($0.05), versus ($0.11) reported last year.
For the three months and six months ended June 30, 2016, the Company recorded a net loss of $1.7 million and $4.0 million, respectively.
Atossa's important recent developments include the following:
- In August, 2016, Atossa Genetics Settled Litigation With Besins Healthcare, to receive Cash Payment of $1.76 Million, License Agreement Terminated
- In June 2016, Atossa Genetics Initiated an Additional Drug Development Program with Oral Endoxifen for Patients Refractory to Tamoxifen
- In May 2016, Atossa Genetics Announced a $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
- In March 2016, Atossa Genetics Opened its Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women with DCIS or Breast Cancer
For earnings history and earnings-related data on Atossa Genetics (ATOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Third Century Bancorp (TDCB) Reports Q1 EPS of $0.28
- Piper Sandler Companies (PIPR) Tops Q1 EPS by 67c
- Codorus Valley Bancorp (CVLY) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!